![logo](/logos/SNDX.webp)
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
19.1 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Syndax Pharmaceuticals, Inc. |
Symbool | SNDX |
Munteenheid | USD |
Prijs | 19.1 |
Beurswaarde | 1,625,341,240 |
Dividendpercentage | 0% |
52-weken bereik | 11.215 - 25.34 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael A. Metzger M.B.A. |
Website | https://www.syndax.com |
An error occurred while fetching data.
Over Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)